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protein (CRP), are associated with an increased risk of
cardiovascular disease, and it has been suggested that this
association is causal. However, the relationship between
inﬂammation and cardiovascular disease has not been
extensively studied in patients with chronic kidney disease.
To evaluate this, we used data from the Study of Heart and
Renal Protection (SHARP) to assess associations between
circulating CRP and LDL cholesterol levels and the risk of
vascular and non-vascular outcomes. Major vascular events
were deﬁned as nonfatal myocardial infarction, cardiac
death, stroke or arterial revascularization, with an
expanded outcome of vascular events of any type. Higher
baseline CRP was associated with an increased risk of major
vascular events (hazard ratio per 3x increase 1.28; 95%
conﬁdence interval 1.19-1.38). Higher baseline LDL
cholesterol was also associated with an increased risk of
major vascular events (hazard ratio per 0.6 mmol/L higher
LDL cholesterol; 1.14, 1.06-1.22). Higher baseline CRP was
associated with an increased risk of a range of non-vascular
events (1.16, 1.12-1.21), but there was a weak inverse
association between baseline LDL cholesterol and non-
vascular events (0.96, 0.92-0.99). The efﬁcacy of lowering
LDL cholesterol with simvastatin/ezetimibe on major
vascular events, in the randomized comparison, was similar
irrespective of CRP concentration at baseline. Thus,
decisions to offer statin-based therapy to patients with
chronic kidney disease should continue to be guided by
their absolute risk of atherosclerotic events. Estimation of
such risk may include plasma biomarkers of inﬂammation,
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I nﬂammation has been implicated in the pathobiology ofcardiovascular disease,1,2 but it is unclear whether inﬂam-mation is a direct cause of disease or simply a marker of
disease response. Among apparently healthy individuals,
prospective cohort studies have shown that markers of
inﬂammation, such as C-reactive protein (CRP)3 and inter-
leukin-64,5 (IL-6), are positively associated with an increased
risk of cardiovascular events, and studies employingMendelian
randomization have suggested that the association between
IL-6 and risk may be causal.6 Prospective studies have also
shown that low-density lipoprotein cholesterol (LDL-C) is
positively associated with risk of major vascular events,7,8 while
randomized trials of statins9 (and, more recently, of proprotein
convertase subtilisin/kexin type 9 or PCSK-9 inhibitors10) have
shown that lowering LDL-C reduces cardiovascular risk,
conﬁrming that LDL-C is a cause of atherosclerotic disease. It is
unclear whether the presence of inﬂammation inﬂuences the
relationship between LDL-C and cardiovascular disease. Some
groups have suggested, based on experimental studies, that
the presence of inﬂammation may reduce the efﬁcacy of
statin therapy,11 but others have reported — albeit
in nonrandomized analyses of randomized trials of statin
therapy — that greater reductions in CRP with a statin are
associated with larger reductions in cardiovascular risk.12,13
Observational studies previously suggested that cholesterol
might not be associated with increased cardiovascular risk in
patients with chronic kidney disease (CKD).14–16 By contrast,
the Study of Heart and Renal Protection (SHARP, which1
Table 1 | Baseline characteristics by C-reactive protein group









CRP (mg/l) (median, IQR) 1.2 (0.7–2.0) 7.1 (4.6–13.5) -
Age at randomization
(yrs)
61 (12) 63 (12) 62 (12)
Men 2630 (61%) 2773 (64%) 397 (60%)
Prior vascular disease 576 (13%) 733 (17%) 84 (13%)
Diabetes 917 (21%) 1034 (24%) 143 (21%)
Current smoker 532 (12%) 615 (14%) 87 (13%)
Diastolic blood pressure
(mm Hg)
80 (12) 78 (13) 78 (13)
Systolic blood pressure
(mm Hg)
139 (21) 139 (23) 140 (22)
LDL cholesterol (mmol/l) 2.82 (0.89) 2.74 (0.86) 2.70 (0.85)
HDL cholesterol (mmol/l) 1.17 (0.35) 1.06 (0.32) 1.10 (0.26)
Apolipoprotein A1 (mg/dl) 139 (29) 128 (28) 136 (30)
Apolipoprotein B (mg/dl) 96 (26) 97 (25) 94 (25)
Albumin (g/l) 40.7 (3.6) 39.5 (3.7) -
Body mass index (kg/m2) 25.8 (4.5) 28.3 (6.1) 27.3 (6.0)
Ethnicity
White 2944 (68%) 3258 (76%) 444 (67%)
Black 88 (2%) 120 (3%) 56 (8%)
Asian 1150 (27%) 803 (19%) 133 (20%)
Other/not speciﬁed 116 (3%) 124 (3%) 34 (5%)
Co-medication
Antiplatelet therapy 852 (20%) 1112 (26%) 141 (21%)
ACE inhibitor or ARB 2447 (57%) 2263 (53%) 320 (48%)
Beta blocker 1620 (38%) 1657 (38%) 237 (36%)
Calcium channel
blocker
1891 (44%) 1694 (39%) 255 (38%)
Renal status
Not on dialysis 3188 (74%) 2631 (61%) 426 (64%)
On dialysis 1110 (26%) 1674 (39%) 241 (36%)
MDRD-estimated GFR
(ml/min per 1.73m2)a,b
Mean (SD) 26.9 (13.7) 26.2 (12.2) 25.4 (12.4)
$60 61 (2%) 26 (1%) 1 (0%)
$30 to <60 1159 (36%) 924 (35%) 72 (34%)
$15 to <30 1315 (41%) 1162 (44%) 88 (42%)
<15 652 (20%) 518 (20%) 49 (23%)




Median (IQR) 206 (50–725) 206 (51–645) 206 (206–206)
<30 584 (20%) 481 (20%) 42 (22%)
$30 to #300 1120 (38%) 925 (39%) 63 (32%)
>300 1280 (43%) 987 (41%) 90 (46%)
Not available 204 238 231
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CRP,
C-reactive protein; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; IQR,
interquartile range; LDL, low-density lipoprotein; MDRD, Modiﬁcation of Diet in Renal
Disease Study.
Data are n (%), mean (SD), or median (IQR).
aAmong patients not on dialysis.
bPercentages exclude participants for whom data were not available for that
category.
c l i n i ca l t r i a l BC Storey et al.: LDL cholesterol lowering and inﬂammationrandomized 9270 patients with CKD to simvastatin 20 mg
plus ezetimibe 10 mg daily or matching placebo), reported
that during a median follow-up of 4.9 years, a mean reduction
of 0.85 mmol/l LDL-C reduced the risk of major atheroscle-
rotic events (a composite of nonfatal myocardial infarction
[MI], coronary death, nonhemorrhagic stroke, and arterial
revascularization) by 17%, (rate ratio 0.83, 95% conﬁdence
interval [CI] 0.74–0.94). Furthermore, the strength of the
causal association was comparable to that observed in trials
among people without CKD.9,17 The most likely explanation
for the discrepancy between observational studies and SHARP
is that nonrandomized studies in patients with CKD are
subject to “reverse causality,” whereby CKD (or comorbid
disease) causes both lower LDL-C and an increased risk of
death, thereby creating an apparent association between low
cholesterol concentrations and death.18,19
In patients with CKD, inﬂammation is independently
associated with an increased risk of cardiovascular disease.20–22
It has been suggested that LDL-C may not be associated with
cardiovascular disease among patients with evidence of
inﬂammation. In one study of 823 incident dialysis patients,
77% of whom were deﬁned as having evidence of inﬂamma-
tion (albumin < 36 g/l, CRP$10 mg/l, or IL-6$3.09 pg/ml),
non–high-density lipoprotein cholesterol (non-HDL-C, a
close correlate of LDL-C) was not associated with cardiovas-
cular mortality overall (hazard ratio [HR] per 1 mmol/l higher
non-HDL-C 0.97; 95% CI 0.86–1.10), but there was a signif-
icant association (HR 2.09; 95% CI 1.02–4.27) among patients
without evidence of inﬂammation.23
The SHARP trial provides a further cohort in which to
explore the associations of inﬂammation and LDL-C, because
cardiovascular (and nonvascular) outcomes were systemati-
cally recorded and measures of lipid proﬁle and CRP were
taken at baseline and (in a subset of patients) at follow-up.
This affords the opportunity to examine: (i) the association
of CRP with risk of cardiovascular disease; (ii) the associa-
tions, in randomized and observational analyses, of LDL-C
with risk of cardiovascular disease; (iii) whether the degree
of underlying inﬂammation modiﬁed the strength of the
association between LDL-C and cardiovascular risk in this
population; and (iv) the separate associations of CRP and of
LDL-C with nonvascular outcomes.
RESULTS
Among 9270 patients randomized to simvastatin/ezetimibe
versus placebo, 8603 had a plasma CRP concentration
measured at baseline. Compared with patients with baseline
CRP<3 mg/l, patients with CRP$3mg/l were older (63 vs. 61
years),more likely to bemale, (64%vs. 61%), had a higher body
mass index (28.3 vs. 25.8 kg/m2), had more prior vascular
disease (17% vs. 13%), and were more likely to be on dialysis
(39% vs. 26%). Mean LDL-C was slightly lower among those
with higher CRP (2.74 vs. 2.82 mmol/l) (Table 1).
During a median follow-up of 4.9 years, 2317 patients
experienced at least 1 vascular event of any type; 1406 such
events were adjudicated to be atherosclerotic and 1342 were2nonatherosclerotic. Of 2317 vascular events of any type, 1515
met the deﬁnition of major vascular events.
Among 962 patients with measurements of CRP and
LDL-C at both baseline and 2.5 years, allocation to simva-
statin/ezetimibe produced an average 0.99 mmol/l (SE 0.06
mmol/l) reduction in LDL-C (or a 35% [SE 2.0] proportionalKidney International (2017) -, -–-
BC Storey et al.: LDL cholesterol lowering and inﬂammation c l i n i ca l t r i a lreduction) with similar absolute (and proportional) re-
ductions irrespective of baseline CRP (Table 2). Allocation to
simvastatin/ezetimibe produced an average 0.23 (SE 0.08) log
mg/l reduction in log CRP, which equated to a 21% (SE 7.1)
proportional reduction. In terms of the effect size relative to
the SD of baseline measurements, allocation to simvastatin/
ezetimibe had a greater effect on LDL-C (1.1 SD difference)
than log CRP (0.2 SD difference).
Association between C-reactive protein and vascular events
Each 3-fold increase in usual CRP (or, equivalently, 1 SD higher
usual log CRP) was associated with 28% higher major vascular
event (MVE) risk (HR 1.28, 1.19–1.38; Figure 1a), and was
similar irrespective of baseline LDL-C (HRs 1.39 [1.24–1.56] if
LDL-C <2.72 mmol/l vs. 1.22 [1.10–1.35] if LDL-C $2.72
mmol/l, P for interaction¼ 0.07, Supplementary Table S1). The
association between usual CRP and vascular events of any type
was of similar magnitude (1.28 [1.20–1.36]; Supplementary
Figure S2B), and this association was similar for both athero-
sclerotic (1.21, 1.12–1.31) and nonatherosclerotic vascular
events (1.34, 1.23–1.45; Supplementary Figures S2C and S2D;
P for difference ¼ 0.09).
Association between LDL-cholesterol and vascular events
Among the 9270 randomized patients, allocation to simva-
statin/ezetimibe reduced the risk of MVE by 15% (risk ratio
[RR] 0.85, 0.77–0.94, P ¼ 0.0012). In nonrandomized
(observational) analyses; however, usual LDL-C was only
weakly associated with risk of MVE, with each 0.6 mmol/l in-
crease in (or 1 SD higher) LDL-C associated with a 14%
increased risk of MVE (HR 1.14, 95% CI 1.06–1.22; Figure 1c
and Supplementary Figure S3A). The association between
usual LDL-C and vascular events of any type was also weaklyTable 2 | Effect of allocation to simvastatin plus ezetimibe on ch
baseline and study midpoint (2.5 yr)







Changes in log CRP (log mg/l)
All patients 962 1.1 (1.3) –0.11 (0.06)
Baseline LDL-C (mmol/l)
<2.72 464 1.1 (1.4) –0.12 (0.08)
$2.72 498 1.1 (1.3) –0.10 (0.08)
Baseline CRP (mg/l)
<3 473 0.03 (0.73) 0.25 (0.07)
$3 489 2.13 (0.83) –0.49 (0.08)
Changes in LDL-C (mmol/l)
All patients 962 2.79 (0.88) –1.19 (0.04)
Baseline LDL-C (mmol/l)
<2.72 464 2.1 (0.4) –0.77 (0.05)
$2.72 498 3.4 (0.7) –1.57 (0.06)
Baseline CRP (mg/l)
<3 473 2.84 (0.94) –1.22 (0.06)
$3 489 2.74 (0.82) –1.17 (0.06)
CRP, C-reactive protein; LDL, low-density lipoprotein; LDL-C, LDL cholesterol.
Only patients with samples of both LDL cholesterol and CRP at baseline and 2.5 years we
70% irrespective of baseline LDL-C or CRP.
Kidney International (2017) -, -–-positive (HR per 0.6 mmol/l 1.06, 1.00–1.12; Supplementary
Figure S3B), reﬂecting a positive association with atheroscle-
rotic vascular events (HR per 0.6 mmol/l 1.19, 1.11–1.28) but
no signiﬁcant association with nonatherosclerotic vascular
events (HRs per 0.6 mmol/l 0.90, 0.83–0.97; Supplementary
Figure S3C and S3D; P for difference < 0.0001).
Inﬂuence of CRP on association between LDL-C and vascular
events
In the randomized comparison of simvastatin/ezetimibe versus
placebo, the proportional risk reduction was similar in those
with CRP<3mg/l (RR 0.83, 0.71–0.97) and CRP$3 mg/l (RR
0.86, 0.75–0.99; P for interaction ¼ 0.74; Figure 2a). The
interactions between baseline CRP and risk reductionwere also
nonsigniﬁcant in the nondialysis and dialysis subgroups
separately (Supplementary Figure S4). In the observational
analyses, the association was also similar irrespective of
baseline CRP (HRs for ;<3mg/l vs.$3mg/l: 1.15, 1.03–1.27 vs.
1.18, 1.08–1.30; P for heterogeneity ¼ 0.67, Supplementary
Table S1).
Associations between CRP or LDL-C and nonvascular
outcomes
Each 1 SD increase in usual CRP was associated with a 16%
higher risk of any nonvascular outcome (HR 1.16, 1.12–1.21;
Figure 1b). The strongest association was with respiratory
events (HR 1.37, 1.27–1.48), but all types of nonvascular
event had a statistically signiﬁcant positive association with
usual CRP (Supplementary Figure S5).
By contrast, allocation to simvastatin/ezetimibe had no
effect on the risk of nonvascular events (RR 0.99, 0.95–1.04,
P ¼ 0.82), regardless of baseline CRP (P for interaction ¼
0.96; Figure 2). In observational analyses, there was a weakanges in concentrations of LDL cholesterol and CRP between
in mean concentration (SE)











0.12 (0.05) –0.23 (0.08) –21% (7.1) –0.2 (0.06)
0.09 (0.08) –0.21 (0.11) –19% (10.2) –0.2 (0.08)
0.15 (0.07) –0.25 (0.11) –23% (9.9) –0.2 (0.08)
0.51 (0.07) –0.26 (0.10) –804% (308.9) –0.4 (0.14)
–0.24 (0.07) –0.25 (0.11) –12% (5.1) –0.3 (0.13)
–0.21 (0.04) –0.99 (0.06) –35% (2.0) –1.1 (0.06)
0.13 (0.04) –0.90 (0.06) –43% (3.0) –2.0 (0.14)
–0.53 (0.05) –1.04 (0.08) –30% (2.3) –1.5 (0.11)
–0.32 (0.05) –0.90 (0.08) –32% (2.7) –1.0 (0.08)
–0.10 (0.05) –1.07 (0.08) –39% (3.0) –1.3 (0.10)





















































































HR per 0.6 mmol/l higher usual LDL−C
0.96 (0.92−0.99)
d
Figure 1 | Association between usual C-reactive protein (CRP) and the risk of (a) major vascular events and (b) nonvascular events, and
the association between usual low-density lipoprotein cholesterol (LDL-C) and the risk of (c) major vascular events and (d) nonvascular
events. Hazard ratios (HRs) adjusted for age, sex, ethnicity, treatment allocation, prior diabetes, prior vascular disease, smoking, body mass
index, high-density lipoprotein cholesterol, and renal status are noted (above squares), along with numbers of events (below squares). Average
HR (95% conﬁdence interval [CI]) throughout the range of values studied (i.e., assuming a log-linear relationship for LDLC and a log-log-linear
relationship for CRP), corresponding to about 1 SD difference in the usual LDLC/log CRP.
c l i n i ca l t r i a l BC Storey et al.: LDL cholesterol lowering and inﬂammationinverse association between usual LDL-C and the composite
of all nonvascular outcomes (HR per 0.6 mmol/l 0.96, 0.92–
0.99; Figure 1d) and this association appeared qualitatively
similar for each of the disease categories studied
(Supplementary Figure S6).
DISCUSSION
This study provides several insights into the inter-relationships
between inﬂammation (as measured by CRP), LDL-C, and4cardiovascular disease in a populationwithmoderate-to-severe
CKD. CRP has previously been shown to be positively associ-
ated with all-cause mortality in studies among patients with
CKD,24,25 but its association with vascular events has been
uncertain.21,24 This study shows clearly that CRP is associated
with both atherosclerotic and nonatherosclerotic vascular
disease, as well as many nonvascular diseases.
Although our study cannot directly address the question of
whether inﬂammation causes cardiovascular disease, itsKidney International (2017) -, -–-
ab





Figure 2 | Effect of allocation to simvastatin plus ezetimibe on (a) major vascular events and (b) nonvascular events by level of
C-reactive protein. CI, conﬁdence interval; LDL-C, low-density lipoprotein cholesterol.
BC Storey et al.: LDL cholesterol lowering and inﬂammation c l i n i ca l t r i a lresults do not provide any support for this hypothesis in
patients with CKD. CRP was positively associated with both
atherosclerotic and nonatherosclerotic vascular events.
Furthermore, positive associations were observed between
CRP and a wide range of nonvascular outcomes in different
body systems. Although counter-examples exist (e.g., cigarette
smoking causes a range of vascular and nonvascular condi-
tions),26 this lack of speciﬁcity is in contrast to the speciﬁcity
of the association of LDL-C with atherosclerotic vascular
events in this study and other randomized trials of statin
therapy. As originally proposed by Hill,27 a nonspeciﬁc as-
sociation of an exposure with many unrelated outcomes is
evidence against a causal association.
The previously reported main results of the randomized
comparison in SHARP demonstrated that LDL-C is a cause of
atherosclerotic disease in people with CKD, and that the
strength of the association is comparable to that observed in
people without CKD.17 This suggests that previous observa-
tional studies in which the association between cholesterol
and cardiovascular disease was weak28 or absent14–16 may
have been subject to bias and confounding. In the present
observational analyses of SHARP, the relationship between
LDL-C and cardiovascular disease was weaker than would be
expected. The results of our study reinforce the importance of
careful phenotyping of cardiovascular events when exploring
associations between a biomarker and such outcomes in
patients with CKD, because there was clear evidence that the
association between usual LDL-C and atherosclerotic vascular
events was positive (as expected), whereas the association
with nonatherosclerotic vascular events (e.g., heart failure and
arrhythmias) was inverse. This suggests that studies that do
not discriminate between vascular events of different etiology,
as for example when examining associations with “cardio-
vascular mortality,” may be misleading.15,23
Our study highlights the potential dangers of relying on
observational studies to determine the role of inﬂammation in
determining the effects of lowering LDL-C in this population.
An analysis of an observational study, for example, was theKidney International (2017) -, -–-basis for a previous claim that cholesterol may not be asso-
ciated with cardiovascular risk in dialysis patients in whom
there is evidence of inﬂammation.23 The present randomized
study shows clearly that reducing LDL-C is effective irre-
spective of inﬂammatory status, as measured by baseline CRP.
This is consistent with previous analyses of the Heart Pro-
tection Study (the largest statin trial which included patients
with a broad range of baseline CRP values) and in other statin
trials, including 2 conducted in hemodialysis patients, all of
which found no evidence that the proportional effects of
statin therapy differed according to baseline CRP.29–32
Whereas inﬂammation is a feature of atherosclerosis, it re-
mains unclear whether it is a cause of disease. Mendelian
randomization (MR) studies in people without CKD indicate
that genetic variants associated with higher CRP concentrations
are not associated with higher vascular risk; that is, the CRP
molecule itself is not a cause of atherosclerosis.33 MR studies of
more proximal biomarkers of inﬂammation (e.g., IL-6) do,
however, suggest a causal relationship between IL-6 and vascular
disease.6 This hypothesis may be supported by the recent results
of a trial of the anti-inﬂammatory agent canakinumab (an IL-1b
antagonist), which has reported a positive result.34
It has previously been claimed that statins are most
effective in the presence of inﬂammation and that patients
achieving the greatest CRP reductions due to statin therapy
experience the largest risk reductions, which would be
consistent with a causal role for inﬂammation in athero-
sclerosis.13 This type of analysis is subject to bias, however,
because the types of patients in whom larger reductions in
CRP are achieved differ in other ways from those achieving
smaller reductions, and adjustment for such differences may
not be possible using recorded variables. Unbiased assess-
ment of the role of the magnitude of reductions in CRP (as a
marker for the degree of attenuation of the inﬂammatory
response) would require the magnitude of change in CRP to
be measured among all patients before randomization (e.g.,
during a “run-in” period on active drug). Alternatively,
evidence of a larger effect among those with higher baseline5
c l i n i ca l t r i a l BC Storey et al.: LDL cholesterol lowering and inﬂammationCRP (or other indices of inﬂammation) may emerge from
randomized controlled trials of anti-inﬂammatory therapies
that are currently testing whether reducing inﬂammation can
reduce vascular risk,36 although this was not observed in a
recent trial of anti-IL-1ß therapy.34,35
Our analyses had a number of limitations. Analyses of the
SHARP trial as an observational study may be subject to
collider bias when exploring associations between baseline
measures and outcomes, because patients were highly selected
(e.g., for the presence of CKD).37 A further limitation was
that CRP was not measured in all patients during follow-up,
so we were unable to determine the change in CRP among
patients with different baseline levels of CRP. The strengths of
the study include the detailed phenotyping of patients at
baseline and adjudication of events occurring after random-
ization, and the central laboratory measurement of LDL-C
and CRP, with repeat measures allowing correction for
regression dilution.38 Most importantly, the trial provided an
unbiased test of the etiological role of LDL-C among patients
with different levels of inﬂammation through randomization
to simvastatin/ezetimibe versus placebo.
In conclusion, our results show that both LDL-C and CRP
are positively associated with the risk of MVE among patients
with CKD, and that the association between LDL-C and car-
diovascular disease is not signiﬁcantly dependent on the
severity of any underlying inﬂammatory response. The current
recommendation that LDL-C–lowering therapy is offered to
patients with CKD based chieﬂy on their absolute risk remains
valid,39 and although this risk may be estimated with a risk
score that includes data on inﬂammatory response, indices of
inﬂammation in isolation should not inﬂuence such decisions.
METHODS
Study design and participants
Details of the SHARP trial objectives, design, and methods have been
reported previously.40 In brief, SHARP was an international,
prospective, randomized controlled trial of people aged 40 years and
older. Eligible participants had more than 1 previous measurement
of serum or plasma creatinine of at least 150 mmol/l (1.7 mg/dl) in
men or 130 mmol/l (1.5 mg/dl) in women, whether they were
receiving dialysis or not. Participants with prior MI or coronary
revascularization were excluded. Potentially eligible participants
attended a screening visit at which a medical and drug history and
anthropometric and blood pressure measurements were recorded
and informed consent obtained. The study is registered at
ClinicalTrials.gov (NCT00125593 and ISRCTN54137607). Ethics
approval was obtained at all study sites before enrollment.
After 6 weeks of placebo run-in, eligible participants were
randomized at a ratio of 4:4:1 to simvastatin 20 mg plus ezetimibe 10
mg (as a single tablet), placebo, or simvastatin 20 mg alone, with
treatment allocation masked using a double-dummy method. After 1
year, those patients allocated to simvastatin alone who were alive and
willing to continue were re-randomized to simvastatin/ezetimibe or
placebo.
Study procedures
Scheduled clinic visits were at 2 and 6 months after randomization
and thereafter at 6 monthly intervals until the study end. Information6was recorded at each follow-up about any suspected MI, stroke,
vascular procedure, cancer, other reasons for hospital admissions, or
other serious adverse events (SAEs). If a participant became unwilling
or unable to attend follow-up visits, information about SAEs was
obtained from them (or their relative or carer) by telephone or from
their physicians until the scheduled end of the study. Local study staff
then sought extra information from hospital records and other
appropriate sources about all reports of SAEs that might relate to the
trial’s major outcomes (MVE: a composite outcome consisting of
nonfatal MI, cardiac death, nonfatal or fatal stroke, and arterial
revascularization, excluding dialysis access procedures; end-stage
renal disease; cancer; and death). This information was sent to the
international coordinating center for central adjudication, in accor-
dance with pre-speciﬁed deﬁnitions, by trained clinicians who were
masked to study treatment allocation. For the current report, the
main analyses are of MVEs and nonvascular events (subdivided into
cancer, renal, respiratory, hepatobiliary or gastrointestinal, and other
medical or trauma SAEs).41 In order to investigate the association
between CRP, LDL-C, and different types of vascular disease further,
we speciﬁed an expanded outcome of “vascular events of any type,”
deﬁned as atherosclerotic events (nonfatal MI, coronary death,
arterial revascularization, unstable angina, heart failure due to
coronary disease, ischemic stroke, transient ischemic attack, aortic
aneurysm, limb ischemia, embolism, or thrombosis) and
nonatherosclerotic vascular events (noncoronary cardiac death, heart
failure not related to ischemic heart disease, arrhythmias, valvular
heart disease, pericardial disease, hemorrhagic stroke, or subarach-
noid hemorrhage) (Supplementary Appendix).
Blood and urine samples were collected from all participants at
baseline and 2.5 years after randomization. In addition, for a random
sample of 10% of participants, further blood samples were collected at
1 and 4 years after randomization. LDL-C was measured on a Beck-
man Coulter (Brea, CA) LX20/DxC 800 in all participants at all times,
with a maximum coefﬁcient of variation (CV) of 2.71%. CRP was
measured on a Siemens (Washington, DC) BN ProSpec system with a
maximum CV of 3.11%. CRP was measured in all participants at
baseline and in a randomly selected 10% of participants at 2.5 years.
Statistical analyses
For observational analyses, the associations between “usual” (i.e.,
long-term average) CRP or LDL-C and MVE were estimated using
Cox proportional hazards regression, with the proportional hazard
assumption tested through examination of the time-dependency of
the Schoenfeld partial residuals. Regression dilution ratios were
calculated from the 2.5-year repeat measurements of LDL-C and
CRP (which only requires repeat measurements in a subset of
participants) and a standard correction applied to the corresponding
HRs.38 Based on assumptions about causal relationships between
measured characteristics and outcomes42 (see directed acyclic graph;
Supplementary Figure S1), analyses were adjusted for age, sex,
ethnicity (white, black, Asian, or other), treatment allocation, prior
disease (including diabetes mellitus and vascular disease), smoking
status (current, former, or never), body mass index, HDL choles-
terol, and renal status (estimated glomerular ﬁltration rate
[eGFR] $30 ml/min per 1.73m2; eGFR $15 to <30 ml/min per
1.73m2; eGFR <15 ml/min per 1.73m2; or on dialysis). Participants
with missing values for CRP or LDL-C were excluded from the
relevant analyses.
In ﬁgures, participants are grouped into 4 categories containing
similar numbers of events, with the HR for each group plotted against
the mean CRP or LDL-C concentration at the study midpoint andKidney International (2017) -, -–-
BC Storey et al.: LDL cholesterol lowering and inﬂammation c l i n i ca l t r i a laccompanied by a CI derived only from the variance of the log risk in
that single group. Hence, each HR, including that for the reference
group, is associated with a group-speciﬁc CI that can be thought of as
reﬂecting the amount of data only in that 1 group, and allowing
appropriate statistical comparisons to be made between any 2
groups.43
We conducted (post hoc) intention-to-treat analyses of the effect
of allocation to simvastatin/ezetimibe on time to ﬁrst MVE among
patients below or above the median CRP (<3 mg/l, $3 mg/l).
Standard log-rank methods were used to provide estimates of
average event rate ratios, associated 95% CIs, and 2-sided P values.
Standard chi-square tests for heterogeneity were used to compare
event rate ratios between subgroups deﬁned by baseline CRP. P
values <0.05 were deemed to be conventionally statistically signiﬁ-
cant, but when interpreting the clinical relevance of ﬁndings, the post
hoc nature of the analyses, the number of events available, and the
magnitude of the P value were all considered.
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